MultiHance (gadobenate dimeglumine) is a gadolinium based contrast agent manufactured by Bracco Diagnostics. The FDA approved Multihance in 2004 for use in magnetic resonance imaging (MRI) of the central nervous system in adults. It helps provide doctors with clear pictures of organs and tissue abnormalities in the body during MRI imaging scans. Healthcare professionals often inject MultiHance into a patient’s bloodstream before an imaging scan in order to enhance the images.

The active ingredient in Multihance is gadolinium. In most healthy patients, gadolinium is quickly flushed out of the body by the kidneys. However, in patients with kidney problems, the gadolinium may remain in the body, resulting in the patient developing Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD). This is a potentially fatal disease that causes skin to swell and tighten, leaving patients unable to extend their limbs.

Due to the risk of NSF, the FDA now requires all gadolinium contrast agents to have warning labels. In addition, gadolinium lawsuits have been filed by patients with NSF naming Bracco Diagnostics and other gadolinium contrast agent manufacturers as the defendants. MultiHance lawsuits are being investigated and reviewed for individuals with kidney disease who were injected with the MultiHhance contrast agent during an MRI or MRA and subsequently developed Nephrogenic Systemic Fibrosis.

If you were injected with Multihance contrast agent for an MRI and have been diagnosed with NSF, you may have a legal right to compensation. Fill out the form on the right side of this page for a free case evaluation and information about your legal rights.